Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Nachman

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 13, 2012
Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South AfricaC A Beneri, B Zeldow, S Nachman, et al.
Clinical Pharmacology and Therapeutics|July 14, 2001
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infectionM Mirochnick, E Cooper, E Capparelli, et al.
The Pediatric Infectious Disease Journal|June 3, 1999
Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials GroupK McIntosh, E Cooper, J Xu, et al.
British Journal of Clinical Pharmacology|September 3, 2025
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the NetherlandsD Nerguizian, Z Wei, G Aldrovandi, et al.
AIDS Research and Human Retroviruses|August 24, 2000
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study TeamA Wiznia, K Stanley, P Krogstad, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 17, 2013
Requirements for the clinical evaluation of new anti-tuberculosis agents in childrenP R Donald, A Ahmed, W J Burman, et al.
The Journal of Infectious Diseases|May 24, 2000
Group-specific antibody levels surrounding invasive pneumococcal illness in children infected with human immunodeficiency virusJ C King, W Borkowsky, N Mahidhara, et al.
HIV Medicine|March 28, 2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsE V Capparelli, F Aweeka, J Hitti, et al.
Antimicrobial Agents and Chemotherapy|October 30, 1999
Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected childrenM Mirochnick, E Cooper, K McIntosh, et al.
Vaccine|May 5, 2015
A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infantsM Tameris, D A Hokey, V Nduba, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 13, 2012
Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South AfricaC A Beneri, B Zeldow, S Nachman, et al.
Clinical Pharmacology and Therapeutics|July 14, 2001
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infectionM Mirochnick, E Cooper, E Capparelli, et al.
The Pediatric Infectious Disease Journal|June 3, 1999
Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials GroupK McIntosh, E Cooper, J Xu, et al.
British Journal of Clinical Pharmacology|September 3, 2025
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the NetherlandsD Nerguizian, Z Wei, G Aldrovandi, et al.
AIDS Research and Human Retroviruses|August 24, 2000
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study TeamA Wiznia, K Stanley, P Krogstad, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 17, 2013
Requirements for the clinical evaluation of new anti-tuberculosis agents in childrenP R Donald, A Ahmed, W J Burman, et al.
The Journal of Infectious Diseases|May 24, 2000
Group-specific antibody levels surrounding invasive pneumococcal illness in children infected with human immunodeficiency virusJ C King, W Borkowsky, N Mahidhara, et al.
HIV Medicine|March 28, 2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsE V Capparelli, F Aweeka, J Hitti, et al.
Antimicrobial Agents and Chemotherapy|October 30, 1999
Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected childrenM Mirochnick, E Cooper, K McIntosh, et al.
Vaccine|May 5, 2015
A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infantsM Tameris, D A Hokey, V Nduba, et al.
Pageof 5